Skip to content
Bramble

Health

Israeli-led Nature study tests blood test for early breast cancer and recurrence risk

A Nature study by Weizmann Institute and Hebrew University researchers found that epigenetic markers in blood could distinguish early breast cancer from healthy samples and flag recurrence risk. The work is early, and outside and study voices say larger studies are needed.

2 outlets · 0L · 1C · 1R First reported Account updated
Image: Newsweek
Image: JNS

1 / 2

The story, neutrally told

Mixed · 2Researchers led by the Weizmann Institute of Science and the Hebrew University of Jerusalem published a study in Nature describing a blood test that can distinguish women with early-stage breast cancer from healthy women and indicate which patients face a higher risk of recurrence. Mixed · 2The test reads epigenetic signatures, chemical marks that control gene activity, on cell-free nucleosomes (DNA wrapped around proteins) that are released into blood when cells die; the team adapted a technology called EPINUC that uses less than one millilitre of plasma. Mixed · 2The researchers first analysed 12 surgically removed, previously untreated tumours, mostly luminal (hormone-receptor-positive), and found a population of cells with a basal-like profile, a type generally linked to more aggressive disease; in laboratory models an aggressive population always eventually emerged, even from non-aggressive cells.

Mixed · 2In an initial group of 77 breast cancer patients and 30 healthy women, the test separated cancer from healthy samples; Newsweek reports AI models distinguished early-stage cancers (confined to the breast, no more than 2 cm) with 95 percent accuracy. Right · 1JNS reports that on a further 188 luminal breast cancer samples, a model trained on 75% of the data and tested on 25% reached an area under the curve (AUC) of 0.96, and a separate Mayo Clinic set gave 0.98. Mixed · 2For recurrence, the 77-patient Mayo Clinic group had at least five years of follow-up; a model using the blood signature predicted relapse with 81 percent accuracy (AUC 0.81), and JNS says this outperformed models based on stage, grade and subtype, while a smaller separate group gave an AUC of 0.92.

Mixed · 2Professor Guy Ron of the Hebrew University said that the more prevalent the aggressive-cell signature was in blood, the greater the risk of the disease returning; Newsweek adds the test flagged recurrence risk in some patients considered low risk by conventional measures. Mixed · 2Professor Efrat Shema of the Weizmann Institute said evidence is mounting that cancer cells use epigenetic flexibility to become more aggressive and evade treatment, and that the findings could help predict recurrence and search for ways to prevent it; JNS adds the work points to a possible therapy targeting these chemical changes. Mixed · 2Context: breast cancer is the most commonly diagnosed cancer among women, with about 2.3 million new cases worldwide in 2022, and Newsweek says it returns in an estimated 20 to 40 percent of cases despite apparently successful treatment.

Centre · 1Dr. Lucy Hooper, a general practitioner and co-founder of Coyne Medical, told Newsweek that larger studies are needed before routine use, noting the study was early, retrospective and largely of hormone-receptor-positive cancers, with samples taken before surgery, and that there is no convincing evidence yet that changing treatment after an early positive result improves outcomes. Right · 1The researchers themselves stressed that further studies are needed to validate the findings and establish whether EPINUC can be used in clinical practice.

Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.

Left0 outlets

No left outlet in our sources has covered this story yet.

Centre1 outlet

Framing
Patient-facing explainer on a possible early-detection and recurrence-risk test, balanced by an outside clinician's caveats.
Emphasis
Accuracy figures, mammography limits in dense breasts, and the need for larger studies.
Leaves out or plays down
Omits the AUC figures from validation sets and the 12-tumour analysis detail.
Charged language
“hidden threat”
For example
“larger studies are needed before the test can be employed routinely” — Newsweek
“making them a hidden threat” — Newsweek

Right1 outlet

Framing
National-achievement angle: an Israeli-developed test, relayed from the TPS-IL news service, with technical detail.
Emphasis
Methodology, AUC scores across cohorts, and potential therapeutic implications.
Leaves out or plays down
Includes no independent expert comment, and states researchers' caveats only briefly; omits that samples were taken before surgery and the study was retrospective.
Charged language
“Israeli blood test”
For example
“Israeli researchers have developed a blood test that can distinguish women with early-stage breast cancer from healthy women” — JNS
“The research also points to a potential new therapeutic approach” — JNS

Ask about this story

Loading…